1Krapinske Toplice Special Hospital for Medical Rehabilitation, Krapinske Toplice, Croatia; 2Faculty of Medicine in Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 3Faculty of Dental Medicine and Health in Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 4Zagreb University Hospital Centre, Zagreb, Croatia; 5School of Medicine, University of Zagreb, Zagreb, Croatia.
Acta Clin Croat. 2022 Feb;60(3):540-543. doi: 10.20471/acc.2021.60.03.26.
Antiplatelet therapy is an integral part of optimal medicamentous therapy in patients with coronary artery disease. The strategy of antiplatelet/anticoagulant therapy is adjusted (combination of drugs, dosing and duration of therapy) depending on the stage of the disease (acute coronary syndrome with percutaneous coronary intervention, chronic coronary syndrome, or coronary surgical revascularization) and comorbidity of each patient (e.g., atrial fibrillation, left ventricular thrombus, etc.). Guidelines and clinical practice in particular are not uniform and specific regarding dual antiplatelet therapy in patients undergoing coronary artery bypass grafting, especially in the setting of chronic coronary syndrome.
抗血小板治疗是冠状动脉疾病患者最佳药物治疗的重要组成部分。抗血小板/抗凝治疗策略（药物组合、剂量和治疗持续时间）取决于疾病阶段（经皮冠状动脉介入治疗的急性冠状动脉综合征、慢性冠状动脉综合征或冠状动脉搭桥手术）和每位患者的合并症（例如，心房颤动、左心室血栓等）。指南和临床实践在接受冠状动脉旁路移植术的患者中尤其在慢性冠状动脉综合征患者中，关于双联抗血小板治疗的具体细节并不统一。
